Vaxil Announces Non-Brokered Private Placement

Core Viewpoint - Vaxil Bio Ltd. is planning a non-brokered private placement to raise up to $350,000 through the issuance of units priced at $0.1425 each, which will include common shares and warrants [1][2]. Group 1: Offering Details - The offering will consist of up to 2,456,140 units, with each unit comprising one common share and one common share purchase warrant [1]. - Each warrant will allow the holder to purchase one share at a price of $0.19 for five years post-closing [1]. - The expected closing date for the offering is around November 14, 2025, pending approval from the TSX Venture Exchange [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to support general corporate purposes [2]. Group 3: Finder's Fees - The company will pay finders a cash commission of up to 8% of the gross proceeds and non-transferrable warrants equal to up to 8% of the total units issued [3]. - The units, shares, and warrants will be subject to a hold period of four months and one day from the issuance date [3]. Group 4: Company Background - Vaxil is an immunotherapy biotech company focused on targeting cancer markers and infectious diseases, with its lead product being ImMucin™, which has received orphan drug status from the FDA and EMA [4]. - The company is exploring other business opportunities that may or may not be within the biotechnology sector to enhance shareholder value [4].